ATLASMadrigal Pharmaceuticals (MDGL) Q3 2026 earnings results
Madrigal Pharmaceuticals (MDGL) reported EPS of $1.83 against an analyst estimate of -$1.09: a beat of $2.92 (267.9%). The quarter ended Sep 30, 2026; the company reported on Tuesday, November 3, 2026, before the open.
Status: Confirmed · 14:37 ET, Nov 3 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after Madrigal Pharmaceuticals reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountMDGL Q3 2026 results at a glance
| EPS reported | $1.83 |
|---|---|
| EPS estimate | -$1.09 |
| Surprise | Beat · +$2.92 (+267.9%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 3, 2026, before the open |
| Status | Confirmed · 14:37 ET, Nov 3 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is Madrigal Pharmaceuticals’s Q3 2026, a calendar-year company.
Madrigal Pharmaceuticals EPS surprise history: last 4 quarters
Madrigal Pharmaceuticals beat the EPS estimate in 4 of its last 4 reports, with an average surprise of +121.7%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 3, 2026 | -$1.09 | $1.83 | +267.9% | Beat | – |
| Jul 28, 2026 | $0.87 | $0.89 | +2.3% | Beat | -0.8% |
| May 6, 2026 | -$4.14 | -$1.38 | +66.7% | Beat | +6.5% |
| Mar 4, 2026 | $0.06 | $0.15 | +150.0% | Beat | +3.2% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
MDGL stock reaction to the report
MDGL moved -8.13% in the first session that reflects the report (close of Nov 2, 2026 $431.16 to close of Nov 3, 2026 $396.09).
Next MDGL earnings report
Madrigal Pharmaceuticals has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the MDGL earnings calendar.
ATLAS fair value and signal for MDGL
| Last price | $456.43 (+5.9%) |
|---|---|
| Chance of a higher close in 1 month | 50% (normal range $426.97–$487.58) |
These are model outputs from the same valuation and calibrated model as the Madrigal Pharmaceuticals stock page. They describe an ordinary period and are not a forecast of any particular outcome.
Madrigal Pharmaceuticals Q3 2026 earnings: frequently asked questions
Did Madrigal Pharmaceuticals beat earnings estimates for Q3 2026?
Madrigal Pharmaceuticals reported EPS of $1.83 against an analyst estimate of -$1.09: a beat of $2.92 (267.9%).
When did Madrigal Pharmaceuticals report Q3 2026 results?
Madrigal Pharmaceuticals reported on Tuesday, November 3, 2026, before the open, for the quarter ended Wednesday, September 30, 2026.
How often does MDGL beat EPS estimates?
In its last 4 reports with a recorded result, Madrigal Pharmaceuticals beat the EPS estimate 4 times; the average surprise was +121.7%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer